Advances in Prostate Imaging and Ablative Treatment of Prostate Cancer
Friday - Saturday
June 19 - 20, 2015
NYU Langone Medical Center
550 First Avenue
Alumni Hall, Farkas Auditorium
New York, NY 10016
*After 12pm on June 17, 2015, only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional $20 fee. Registration is non-transferable.
Herbert Lepor, MD
Full Fee Early Bird: $525 (ends 3/15/15 at 11:59 pm)
Full Fee: $595
Reduced Fee Early Bird**: $515 (ends 3/15/15 at 11:59 pm)
Reduced Fee**: $525
NYU Langone Department of Urology Faculty, Residents and Fellows***: Waived
**Reduced fee applies to NYU School of Medicine alumni, former residents and fellows; physicians-in-training with letter of certification from the Chief of Service; physicians employed by the Department of Veterans Affairs Medical Center; full-time active military personnel; nurse practitioners; retired physicians; and all other non-physician healthcare professionals.
***Must provide valid NYU Langone ID.
The primary goal of this conference is to provide the urologist and radiologist with a comprehensive review of advances in prostate imaging, biopsy, and focal minimally invasive ablative therapy (MIAT) of prostate cancer. The course is designed for practicing and academic urologists and radiologists who are interested in learning about and adopting targeted prostate biopsy and MIAT for managing prostate cancer. Selecting candidates for these novel treatment options will also be emphasized.
The course will be organized into sessions focusing on prostate imaging, prostate biopsy, disease risk stratification and MIAT. The information will be disseminated via lectures, case discussions and panel discussions.
The educational focus is designed to optimize selection of candidates and delivery of MIAT for prostate cancer by: identifying the ideal biopsy strategy in order to reliably assess the extent and biological aggressiveness of the disease; discussing novel tumor markers for improving risk stratification; applying the latest advances in imaging of prostate cancer in order to improve better assessment of the site and extent of clinically significant disease and enable target biopsies; and critically examining the most promising approaches for ablating prostate cancer and presenting technological pearls to maximize outcomes following minimally invasive ablative treatment of prostate cancer.
This course is designed for practicing and academic urologists and radiologists who are interested in learning about, and possibly adopting, both targeted biopsy and minimally invasive ablative therapies for prostate cancer.
Statement of Need
The optimal biopsy strategy for accurate risk stratification of prostate cancer remains controversial. Practicing clinicians need to understand the pros and cons of different biopsy strategies in order to gather the clinical information to optimize treatment decisions and appropriately select men for focal MIAT of prostate cancer.
In the past year, evidence has emerged supporting MRI guided targeted biopsy. A recent survey indicated that a significant proportion of US urologists plan to acquire targeted biopsy technology in 2015. Accordingly, it is important for clinicians to examine the different perspectives on data introduced in the literature regarding diagnosis.
MRI is underutilized in the work-up of men with elevated PSA and prostate cancer. Owing to advances in multiparametric MRI (mpMRI) of the prostate, this imaging modality should be considered in the selection of candidates for biopsy and for focal therapy. While level-one evidence is not available, clinicians need to rely on the experience and consensus of those experts in the field who are investigating the role of mpMRI for localizing prostate cancer. Clinicians (urologists and radiologists) must better understand the advantages of more powerful magnets as well as diffusion imaging and contrast enhancement. Additionally, clinicians need to have strategies for assessing best timing for utilizing MRI imaging post-biopsy following ablative intervention.
There is increasing interest in minimally invasive ablative therapies for prostate cancer, yet few urologists actually offer this option to men with prostate cancer. Clinicians need to understand the various ablative treatment options in order to select the most appropriate treatment strategy and source of ablative energy. It is also important that in learning about the multiple options, clinicians appreciate the reasons why the presenters select specific ablative energy sources and technique in a case-based setting. Random TRUS guided biopsy has been shown to both under and over-stage prostate cancer.
There is new evidence that MRI guided biopsy using cognitive co-registration, co-registration with US or in bore biopsy increases specificity of prostate biopsy without decreasing sensitivity for detecting clinically significant disease. Clinicians need to know the relative benefits of these approaches for improving accuracy of prostate biopsy.
Minimally invasive ablative therapies are technically demanding procedures and clinicians need to be experienced with the equipment and procedures before incorporating them into practice. Clinicians need to learn surgical pearls from experts in the field in order to avoid complications and ensure best outcomes. There are many different options for salvage treatment following failed radiation therapy. As the body of experience with salvage treatments increases, it appears that minimally invasive ablative approaches will markedly decrease morbidity without compromising care.
After participating in this activity, clinicians should be able to:
- Evaluate the merits of 12 core random biopsy vs MRI guided in bore biopsy vs 3D co-registration of MRI and TRUS techniques to optimize assessing site and risk stratification of prostate cancer
- Describe advances in prostatic mpMRI, including contrast enhancement, and diffusion weighted imaging as well as the optimal timing for performing mpMRI post-biopsy
- Describe the ablative properties of HIFU, cryotherapy, laser and VPT, differentiate between focal, hemi-ablation and subtotal gland ablation, and select the most appropriate minimally invasive ablative therapy for management of patients’ with localized prostate cancer
- Evaluate and differentiate between different approaches for using MRI to guide prostate biopsy
- Discuss factors that enhance effectiveness of minimally invasive procedures and establish and utilize treatment strategies that decrease complications
- Analyze benefits and risks of the different treatment options for salvage procedures following recurrent disease after radiation therapy
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The NYU Post-Graduate Medical School designates this live activity for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to request a refund, you must click here to complete and submit our online refund form no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. Fax and email cancellations are not accepted.
Course Cancellation Policy
In the unusual circumstance that this course is cancelled, two weeks' notice will be given and tuition will be refunded in full. The NYU Post-Graduate Medical School is not responsible for any airfare, hotel or other costs incurred.